Major adverse cardiovascular events (MACE) in patients with severe COVID-19 registered in the ISARIC WHO clinical characterization protocol: A prospective, multinational, observational study
| Autor: | Luis Felipe Reyes, Esteban Garcia-Gallo, Srinivas Murthy, Yuli V. Fuentes, Cristian C. Serrano, Elsa D. Ibáñez-Prada, James Lee, Amanda Rojek, Barbara Wanjiru Citarella, Bronner P. Gonçalves, Jake Dunning, Indrek Rätsep, Andre Emilio Viñan-Garces, Christiana Kartsonaki, Jordi Rello, Ignacio Martin-Loeches, Manu Shankar-Hari, Piero L. Olliaro, Laura Merson |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Reyes LF] Universidad de La Sabana, Chía, Colombia. Clínica Universidad de La Sabana, Cundinamarca, Colombia. Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom. [Garcia-Gallo E] Universidad de La Sabana, Chía, Colombia. Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom. [Murthy S] Department of Pediatrics, University of British Columbia, Vancouver, Canada. [Fuentes YV] Universidad de La Sabana, Chía, Colombia. [Serrano CC, Ibáñez-Prada ED] Universidad de La Sabana, Chía, Colombia. Clínica Universidad de La Sabana, Cundinamarca, Colombia. [Rello J] Grup de Recerca Clínica/Innovació en la Pneumònia i Sèpsia (CRIPS), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica En Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: |
Sistema cardiovascular - Malalties - Factors de risc
Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores] Cardiovascular Diseases [DISEASES] virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] Critical Care and Intensive Care Medicine técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] COVID-19 (Malaltia) - Complicacions Other subheadings::Other subheadings::/complications [Other subheadings] enfermedades cardiovasculares [ENFERMEDADES] |
| Zdroj: | Scientia Reyes, L F, Garcia-Gallo, E, Murthy, S, Fuentes, Y V, Serrano, C C, Ibáñez-Prada, E D, Lee, J, Rojek, A, Citarella, B W, Gonçalves, B P, Dunning, J, Rätsep, I, Viñan-Garces, A E, Kartsonaki, C, Rello, J, Martin-Loeches, I, Shankar-Hari, M & Olliaro, P L & Merson, L 2023, ' Major adverse cardiovascular events (MACE) in patients with severe COVID-19 registered in the ISARIC WHO clinical characterization protocol : A prospective, multinational, observational study ', Journal of Critical Care, vol. 77, 154318 . https://doi.org/10.1016/j.jcrc.2023.154318 |
| Popis: | COVID-19; Complications; Mortality COVID-19; Complicacions; Mortalitat COVID-19; Complicaciones; Mortalidad Purpose To determine its cumulative incidence, identify the risk factors associated with Major Adverse Cardiovascular Events (MACE) development, and its impact clinical outcomes. Materials and methods This multinational, multicentre, prospective cohort study from the ISARIC database. We used bivariate and multivariate logistic regressions to explore the risk factors related to MACE development and determine its impact on 28-day and 90-day mortality. Results 49,479 patients were included. Most were male 63.5% (31,441/49,479) and from high-income countries (84.4% [42,774/49,479]); however, >6000 patients were registered in low-and-middle-income countries. MACE cumulative incidence during their hospital stay was 17.8% (8829/49,479). The main risk factors independently associated with the development of MACE were older age, chronic kidney disease or cardiovascular disease, smoking history, and requirement of vasopressors or invasive mechanical ventilation at admission. The overall 28-day and 90-day mortality were higher among patients who developed MACE than those who did not (63.1% [5573/8829] vs. 35.6% [14,487/40,650] p < 0.001; 69.9% [6169/8829] vs. 37.8% [15,372/40,650] p < 0.001, respectively). After adjusting for confounders, MACE remained independently associated with higher 28-day and 90-day mortality (Odds Ratio [95% CI], 1.36 [1.33–1.39];1.47 [1.43–1.50], respectively). Conclusions Patients with severe COVID-19 frequently develop MACE, which is independently associated with worse clinical outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|